Application of a multi-epitope DNA vaccine against viral hemorrhagic septicemia virus type Ⅳa
Archives of Virology · 2025
DOI: 10.1007/s00705-025-06430-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Virology, 2025. Verfasst von Na Gyeong Ryu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Aquatic Life Medicine, Pukyong National University, Busan, 48513, Republic of Korea. Hauptthemen laut MEDLINE: Vaccines, DNA, Novirhabdovirus, Viral Vaccines, Fish Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Viral hemorrhagic septicemia virus (VHSV) is a single-stranded RNA virus that infects both freshwater and marine fish. In Korea, VHSV genotype Ⅳa infects cultured olive flounder (Paralichthys olivaceus) annually. As a prevention strategy against infectious viral diseases, this study aimed to develop a multi-epitope DNA vaccine using in silico methods and evaluate its efficacy in vivo in olive flounder. Cytotoxic T-lymphocyte (CTL), helper T-lymphocyte (HTL), and linear B-lymphocyte (LBL) epitopes of the VHSV glycoprotein were predicted using bioinformatic tools and assembled with the linkers AAY, GPGPG, and KK, respectively. This multi-epitope sequence (359 bp) was then cloned into the pcDNA3.1(+) vector for use as a DNA vaccine, and this construct was named "pMulti". To evaluate the efficacy of the multi-epitope DNA vaccine, olive flounder were vaccinated with PBS, pcDNA3.1(+), or pMulti. The persistence and transcript levels were confirmed up to 28 days post-vaccination (dpv). Moreover, HTL-associated immune-related genes, including MHCII and IFN-γ, were significantly upregulated at 3 dpv. Immunoglobulin M (IgM) production was confirmed by ELISA at 14, 21, and 28 dpv. The protective efficacy of the vaccine was tested by challenging fish with 1×104 PFU of VHSV at 21 dpv, and the relative percent survival (RPS) of pMulti-vaccinated fish was 40% in experiment 1 and 23.08% in experiment 2. Moreover, the hazard ratio for the pMulti vaccine was significantly lower than that for PBS and pcDNA3.1(+) (2.08 and 2.65, respectively). Although these findings demonstrate the potential of multi-epitope-based vaccines against VHSV IVa, additional research involving in vivo evaluation of a subunit vaccine through protein expression is essential for a more conclusive assessment of efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Aquatic Life Medicine, Pukyong National University, Busan, 48513, Republic of Korea.
- Department of Aquatic Life Medicine, Pukyong National University, Busan, 48513, Republic of Korea. kimki@pknu.ac.kr.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Ryu, N. G., Yang, Y. J., & Kim, K. I. (2025). Application of a multi-epitope DNA vaccine against viral hemorrhagic septicemia virus type Ⅳa. Archives of Virology. https://doi.org/10.1007/s00705-025-06430-2
Vancouver
Ryu NG, Yang YJ, Kim KI. Application of a multi-epitope DNA vaccine against viral hemorrhagic septicemia virus type Ⅳa. Archives of Virology. 2025. doi:10.1007/s00705-025-06430-2
BibTeX
@article{Ryu2025,
author = {Ryu, Na Gyeong and Yang, Yun Jung and Kim, Kwang Il},
title = {Application of a multi-epitope DNA vaccine against viral hemorrhagic septicemia virus type Ⅳa},
journal = {Archives of Virology},
year = {2025},
doi = {10.1007/s00705-025-06430-2}
}
EUVIMED